Evidence map›Paper›PMID 38128937›Full record

ArticleBMJ open2023

Impact of a pharmacy-led screening and intervention in people at risk of or living with chronic kidney disease in a primary care setting: a cluster randomised trial protocol.

Wubshet Tesfaye, Ines Krass, Kamal Sud, David W Johnson, Connie Van, Vincent L Versace, Rita McMorrow, Judith Fethney, Judy Mullan, Anh Tran and 8 more

Abstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Wubshet TesfayeThe University of Sydney School of Pharmacy, Sydney, New South Wales, Australia.ORCID 0000-0001-7208-2330
Ines KrassThe University of Sydney School of Pharmacy, Sydney, New South Wales, Australia.
Kamal SudNepean Kidney Research Centre, Department of Renal Medicine, Nepean Hospital, Sydney, New South Wales, Australia.
David W JohnsonCentre for Health Services Research, The University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia.
Connie VanThe University of Sydney School of Pharmacy, Sydney, New South Wales, Australia.
Vincent L VersaceDeakin Rural Health, School of Medicine, Faculty of Health, Deakin University, Melbourne, Victoria, Australia.ORCID 0000-0002-8514-1763
Rita McMorrowDepartment of General Practice and Primary Care, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-2835-9504
Judith FethneySchool of Nursing, The University of Sydney Susan Wakil School of Nursing and Midwifery, Sydney, New South Wales, Australia.ORCID 0000-0003-0716-596X
Judy MullanGraduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
Anh TranNHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
Breonny RobsonKidney Health Australia, Melbourne, Victoria, Australia.
Sanjyot VagholkarMQ Health General Practice, Macquarie University, Sydney, New South Wales, Australia.
Lukas KairaitisDepartment of Renal Medicine, Blacktown Hospital, Sydney, New South Wales, Australia.
Natasa GisevNational Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-0452-8470
Mariam FathimaThe University of Sydney School of Pharmacy, Sydney, New South Wales, Australia.
Vivien TongThe University of Sydney School of Pharmacy, Sydney, New South Wales, Australia.
Natali CoricDepartment of General Practice and Primary Care, The University of Melbourne, Melbourne, Victoria, Australia.
Ronald L CastelinoThe University of Sydney School of Pharmacy, Sydney, New South Wales, Australia ronald.castelino@sydney.edu.au.ORCID 0000-0002-5128-7115

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) is increasingly recognised as a growing global public health problem. Early detection and management can significantly reduce the loss of kidney function. The proposed trial aims to evaluate the impact of a community pharmacy-led intervention combining CKD screening and medication review on CKD detection and quality use of medicines (QUM) for patients with CKD. We hypothesise that the proposed intervention will enhance detection of newly diagnosed CKD cases and reduce potentially inappropriate medications use by people at risk of or living with CKD. METHODS AND ANALYSIS: This study is a multicentre, pragmatic, two-level cluster randomised controlled trial which will be conducted across different regions in Australia. Clusters of community pharmacies from geographical groups of co-located postcodes will be randomised. The project will be conducted in 122 community pharmacies distributed across metropolitan and rural areas. The trial consists of two arms: (1) Control Group: a risk assessment using the QKidney CKD risk assessment tool, and (2) Intervention Group: a risk assessment using the QKidney CKD plus Point-of-Care Testing for kidney function markers (serum creatinine and estimated glomerular filtration rate), followed by a QUM service. The primary outcomes of the study are the proportion of patients newly diagnosed with CKD at the end of the study period (12 months); and rates of changes in the number of medications considered problematic in kidney disease (number of medications prescribed at inappropriate doses based on kidney function and/or number of nephrotoxic medications) over the same period. Secondary outcomes include proportion of people on potentially inappropriate medications, types of recommendations provided by the pharmacist (and acceptance rate by general practitioners), proportion of people who were screened, referred, and took up the referral to visit their general practitioners, and economic and other patient-centred outcomes. ETHICS AND DISSEMINATION: The trial protocol has been approved by the Human Research Ethics Committee at the University of Sydney (2022/044) and the findings of the study will be presented at scientific conferences and published in peer-reviewed journal(s). TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12622000329763).

Indexed as

PharmaciesPharmacyRenal Insufficiency, ChronicAustraliaHumansMulticenter Studies as TopicPragmatic Clinical Trials as TopicPrimary Health CareRandomized Controlled Trials as TopicClinical TrialNEPHROLOGYPrimary Health Care

Identifiers

PMID38128937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.